TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers studying older adults and mice found that reduced activity of the protective protein NRF2 in oligodendrocytes was associated with abnormal myelin, loss of large nerve fibers and faster cognitive decline. The mouse experiments support a possible causal role, but whether drugs targeting this pathway can help older adults is not yet known.
A study published in Nature Medicine links reduced activity of the protective protein NRF2 in myelin-producing brain cells with nerve-fiber damage and faster cognitive decline in older adults. Human brain-tissue findings and experiments in mice point to a possible role for dysfunctional oligodendrocytes, but the research does not show that existing drugs can prevent or reverse age-related decline.
The research, led by scientists from the University of Edinburgh and the UK Dementia Research Institute, examined participants in the Lothian Birth Cohort 1936, whose cognitive abilities have been tracked from childhood into old age. From 1,091 enrolled participants, 866 completed additional cognitive testing after age 70. Assessments between ages 70 and 82 measured memory, processing speed and spatial reasoning. Most participants experienced some decline, but the pace differed.
In brain tissue collected after death from a subset of participants, greater decline was associated with fewer large nerve fibers and an abnormal buildup of myelin, the insulation around nerve fibers that helps signals travel. The researchers reported that these tissue features were associated with the rate of cognitive change, not simply a person’s test performance at one age. The findings are associations in human tissue; they do not by themselves establish that the changes caused the decline.
The team also found lower levels of NRF2 in oligodendrocytes among people with more severe decline. In mice, experimentally lowering NRF2 in these cells led to excess myelin, loss of large nerve fibers and reduced improvement on cognitive tests as the animals aged. Those experiments strengthen the case that NRF2 disruption can affect these cells, although mouse results cannot establish that the same process explains cognitive decline in people.
A New Target in Aging Brain Research
The findings challenge the assumption that oligodendrocytes, which maintain myelin, are uniformly protective. If these cells become impaired with age, their altered function may contribute to damage in the nerve fibers they normally support. That offers researchers a possible biological pathway to investigate alongside other processes involved in cognitive aging.
The study also raises the possibility of testing treatments that affect NRF2 activity. The source report says medications acting on this pathway are already used for other neurological conditions, including multiple sclerosis, and that earlier research found cognitive improvements in people with MS when NRF2 activity was increased. That evidence is not proof of benefit for age-related decline: the disease, treatment goals and patient groups differ. Any application to older adults would require dedicated clinical research.
For readers, the practical takeaway is that this is an early research finding, not a new treatment recommendation. It may help guide future studies, but it does not establish that a person’s cognitive changes arise from oligodendrocyte dysfunction or that an existing medicine is appropriate for them.
Products Worth Considering
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White
Blueair Blue Pure 511i Max Smart Air Purifier
As an affiliate, we earn on qualifying purchases.
From Cohort Tracking to Mouse Tests
The Lothian Birth Cohort gives researchers a long view of cognitive change because participants’ abilities were measured over many decades. In this study, repeated testing in later life helped the team compare the pace of decline with findings in donated brain tissue examined after death. This combination gives the researchers a way to connect measured changes over time with brain structure, while leaving open questions about cause in humans.
Myelin supports efficient signaling along nerve fibers, and oligodendrocytes produce and maintain it. NRF2 regulates genes involved in cellular defenses and normal function. The researchers’ proposed chain is that lower NRF2 activity may impair oligodendrocytes, alter myelin and harm large nerve fibers, with effects on cognition. The human observations and mouse experiments support parts of that account, but do not establish that it is the sole or dominant cause of age-related cognitive decline.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Cause and Treatment Remain Unproven
The human tissue results show an association between cognitive decline, myelin abnormalities, nerve-fiber loss and lower NRF2 levels in oligodendrocytes. They cannot determine whether NRF2 changes began before cognitive decline, resulted from other age-related processes, or were one factor among several. The mouse experiments provide evidence of a possible mechanism in animals, but do not resolve those questions in people.
The source report does not specify how large the tissue subset was, the size of the observed effects, or whether the findings apply across different populations and causes of cognitive impairment. It also does not identify a clinical trial showing that an NRF2-targeting medicine slows age-related decline. Whether any such drug would be safe and effective for this purpose remains unknown.
Testing the Pathway in People
The next step is further research to establish how NRF2 activity and oligodendrocyte changes relate to cognitive trajectories in humans, and whether the pathway can be altered safely. Researchers would need to test any proposed treatment in clinical studies designed specifically for older adults with cognitive decline, measuring both safety and meaningful changes in cognition.
Until those studies are done, existing medicines used for other neurological conditions should not be interpreted as proven treatments for age-related cognitive decline. The findings identify a research direction; they do not establish when a therapy might be available or whether one will ultimately work.
Key Questions
What did the study find?
It linked faster cognitive decline in older adults with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes. Mouse experiments showed similar brain changes after researchers reduced NRF2 in those cells.
What are oligodendrocytes and myelin?
Oligodendrocytes are brain cells that produce and maintain myelin, the insulating coating around nerve fibers. Myelin helps electrical signals travel efficiently through the nervous system.
Does the study prove these cells cause cognitive decline in people?
No. The human findings are associations from brain tissue, while the experiments that directly reduced NRF2 were conducted in mice. The results suggest a possible mechanism but do not prove it causes decline in people.
That has not been established. The study points to a pathway that may warrant treatment research, but it does not show that medicines used for other conditions prevent or treat cognitive decline in older adults.
What research is needed next?
Further human research and clinical trials would be needed to determine whether changing NRF2 activity can safely preserve cognitive abilities in older adults and whether any effects are clinically meaningful.
Source: rss
